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Background: Biologic therapies represent a significant advance in the treatment of psoriasis. 
However, no studies have examined the patient characteristics predictive of biologic treatment 
of psoriasis. The purpose of this study was to ascertain the frequency and predictors of treatment 
of psoriasis with biologics in three European countries, ie, France, Spain, and the UK.
Methods: This was a cross-sectional analysis of physician-recorded demographic and clinical 
data on patients receiving either conventional or biologic treatments for psoriasis. Data were 
drawn from the Adelphi 2007 Psoriasis Disease Specific Program (DSP®), a multinational, 
real-world survey of patients with psoriasis consulting practicing dermatologists. The numbers 
of patients treated with biologic and nonbiologic agents were recorded. Data were subjected to 
bivariate analysis according to treatment regimen (biologic versus nonbiologic). Predictors of 
treatment with biologics were identified by logistic regression analysis.
Results: A total of 2,509 psoriasis patients were included in this study (1,374 from France, 
561 from Spain, and 574 from the UK). Biologic use was most prevalent in Spain (19.4% of 
patients), followed by the UK (9.1%), and France (8.4%). In the logistic regression analysis, 
psoriatic arthritis was a statistically significant predictor of increased biologic use in France 
(odds ratio [OR] 5.38, 95% confidence interval [CI] 3.32–8.77), Spain (OR 2.71, 95% CI 
1.16–6.33), and the UK (OR 8.70, 95% CI 3.65–20.83). Physician-assessed moderate-to-severe 
disease was also a statistically significant predictor of increased biologic use in France (OR 
5.08, 95% CI 2.01–12.82), Spain (OR 11.11, 95% CI 4.33–28.57), and the UK (OR 8.55, 95% 
CI 1.11–66.67). 
Conclusion: In this study, an average of about one tenth of psoriasis patients enrolled in Spain, 
France, and the UK were treated with biologics in 2007. Physician-assessed moderate-to-severe 
disease and presence of psoriatic arthritis were significantly associated with biologic use in all 
three countries. 
Keywords: psoriasis, drug therapy, tumor necrosis factor-alpha, antagonists, inhibitors, der-
matologic agents, therapeutic use
Introduction
Psoriasis is a chronic, genetically based, and immune-mediated inflammatory disorder 
affecting 2%–3% of the Caucasian population in western countries.1 These plaques 
may be localized or widespread across the body.2 The fingernails and toenails are 
involved in 40% of psoriasis cases, with thickening and/or pitting of the nails as com-
mon manifestations.3–5
The chronic inflammation underlying psoriasis affects the joints as psoriatic 
arthritis. The prevalence of psoriatic arthritis among patients with plaque psoriasis 
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ranged from 5.9% to 23.9% (median 11.2%) in eight US 
and  European studies using rheumatologically validated 
 criteria.6  Cardiovascular risk factors such as obesity, meta-
bolic syndrome, and hypertension are frequent comorbidi-
ties of psoriasis,7–10 possibly due to common inflammatory 
pathways.11
In limited (mild) disease, the most commonly used 
therapy is topical with the addition of phototherapy in refrac-
tory cases. In moderate-to-severe psoriasis, phototherapy 
alone combined with systemic therapy or systemic therapy 
alone is recommended. Recent guidelines present the level of 
evidence for the efficacy of the available therapies and give 
recommendations for their use in daily practice.12
Significant advances have been made in the treatment 
of psoriasis with the availability of biologic therapies. 
Biologics approved for the treatment of psoriasis in Europe 
are the tumor necrosis factor-alpha antagonists, ie, inflix-
imab, etanercept, and adalimumab, and the anti-p40 agent, 
ustekinumab.2
European and UK guidelines recommend biologics only 
for patients with moderate-to-severe psoriasis who have not 
responded to or are intolerant of conventional therapies.13–17 
In a recent European consensus, moderate-to-severe pso-
riasis was defined as a body surface area .10 or psoriasis 
area and severity index (PASI) .10 and dermatology life 
quality index (DLQI) .10.18 The British Association of 
 Dermatologists recommends biologics only for patients 
who have severe  psoriasis, defined as a PASI score $10 and 
a DLQI score .10.18 These criteria are less stringent than 
those of the UK National Institute for Health and Clinical 
 Excellence for use of infliximab in psoriasis, which recom-
mend infliximab only for very severe psoriasis, defined as a 
PASI score $20 and a DLQI score .18.19
These guidelines provide insight into which patients are 
eligible for treatment with biologics, but there is little infor-
mation in the literature about the determinants of treatment 
of psoriasis with biologics in clinical practice. This study 
was designed to examine variables associated with biologic 
treatment in populations of psoriasis patients from France, 
Spain, and the UK.
Materials and methods
study design
This was a cross-sectional analysis of physician-recorded 
demographic and clinical data on patients receiving 
treatment for psoriasis. Data were drawn from the Adel-
phi 2007 Psoriasis Disease Specific Program (DSP®), a 
multinational, real-world survey of patients with psoriasis 
consulting practicing dermatologists. Physicians were 
identified from the public lists of health care professionals 
and were screened for eligibility based on the criteria of 
whether they were licensed physicians between 1970 and 
2006, specialized in dermatology, and actively managing ten 
or more psoriasis patients per month. Each physician was 
asked to recruit 8–10 consecutive patients presenting with 
psoriasis in his/her office. One hundred and forty-three phy-
sicians were recruited from France and 61 physicians were 
recruited from both Spain and the UK (n=265) to complete 
a detailed patient record form for patients presenting with 
psoriasis and receiving a prescription for topical agents, 
phototherapy, or systemic treatment during routine visits in 
the calendar year 2007. Patients who were 18 years or older 
and diagnosed as having psoriasis were recruited. Patients 
who had a missing value for age or gender were excluded 
from the data analysis.
Variables
The patient record form included demographics, body mass 
index, disease symptoms and severity determined by PASI 
scores, current and previous treatments, patient-reported 
disease management strategies, the physician’s assessment of 
current severity and severity at diagnosis, the patient’s PASI 
score, and physician-reported reasons for clinical decisions 
and prescribing. PASI scores were based on the extent of 
psoriasis in four specific body surface areas (head, trunk, 
upper limbs, and lower limbs) and the degree of plaque 
erythema (redness), scaling, and thickness as described by 
Fredriksson and Pettersson.20 The numeric PASI score ranges 
from 0 (absence of disease) to 72 (maximal disease). The 
severity of disease was determined from the PASI scores, 
and the proportions of patients with mild (PASI score ,10) 
and moderate-to-severe (PASI score $10) disease. Obesity 
was defined as a body mass index $30. Nonbiologic treat-
ments in this study included topical (eg, corticosteroids, 
vitamin D3), phototherapy (eg, natural sunlight or ultraviolet 
A or B irradiation), and traditional systemic (eg, methotrex-
ate, cyclosporine). Biologics in this study included inflix-
imab, etanercept, adalimumab, and efalizumab.
statistical analysis
Patient characteristics were analyzed descriptively for the 
total study samples from each country and then assessed in a 
bivariate analysis according to treatment with biologics (yes 
or no). The statistical significance of the distributions across 
treatment was determined by Student’s t-test for continuous 
data (age and PASI score) and by chi-square or Fisher’s Exact 
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tests for categorical data (sex [male, female], obesity [yes, no], 
nail involvement [yes, no], and psoriatic arthritis [yes, no]). 
The availability of PASI scores in the Adelphi database was 
,20%, so we developed an algorithm to impute the PASI score 
for missing values. Potential predictors of the PASI score, ie, 
severity of body areas affected (11 specific body areas), symp-
tom severity (15 specific symptoms), and percentage of body 
surface area affected, were introduced stepwise into a multiple 
fractional polynomial model to derive the polynomials that 
best predicted the PASI score for each variable. A generalized 
estimating equations model was used to adjust for clustering 
of the predictors (severity of body areas affected, symptom 
severity, and percentage of body surface area affected). After 
applying this algorithm, the correlation between actual and 
predicted PASI scores was R=0.51.
Physician-assessed severity was classified as mild, mod-
erate, or severe, and the frequencies of each level of severity 
were determined by country. A chi-square test was used to 
determine the statistical significance of differences in the 
frequency distributions. The correlation between PASI scores 
(measured or imputed) and physician-assessed severity (mild, 
moderate, or severe) was then assessed by a Spearman analysis 
in patients for whom both variables were available. We used 
a logistic regression model to estimate the adjusted odds of 
receiving treatment with a biologic. Independent variables were 
age, sex, obesity, physician-assessed severity, PASI score, nail 
involvement, and psoriatic arthritis (defined as in the descrip-
tive analysis). Finally, the severity of disease was determined 
from the PASI scores of patients, and the proportions with 
mild (PASI score ,10) and moderate-to-severe (PASI score 
$10) disease were compared between patients with psoriatic 
arthritis and those with psoriasis only. For all analyses, P,0.05 
was considered to be statistically significant.
Results
Patient characteristics
A total of 2,588 patients with psoriasis were included in this 
study. Seventy-nine patients were excluded due to missing 
values for age or gender. Finally a total of 2,509 psoriasis 
patients were included in the statistical analysis (1,374 from 
France, 561 from Spain, and 574 from the UK, Table 1). 
The mean age ranged from 42.4 years (Spain) to 46.6 years 
(France), and men accounted for 52.4% (UK) to 58.7% 
(Spain) of the population. Patients had been diagnosed 
with psoriasis at a mean of 9.2 (Spain) to 14.8 (UK) years 
earlier. The mean PASI score ranged from 9.6 (Spain) to 
10.4 (UK). The proportion of patients with psoriatic arthritis 
ranged from 6.2% (Spain) to 13.0% (UK). Approximately T
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Table 2 Patient treatment by country
All patients 
(n=2,509)
France 
(n=1,374)
Spain 
(n=561)
UK 
(n=574)
Biologic treatment 282 (11.2%) 125 (9.1%) 109 (19.4%) 48 (8.4%)
nonbiologic treatment 2,227 (88.8%) 1,249 (90.9%) 452 (80.6%) 526 (91.6%)
 Topical 1,257 (50.1%) 777 (56.6%) 295 (52.6%) 185 (32.2%)
 Phototherapy 276 (11.0%) 182 (13.2%) 31 (5.5%) 63 (11.0%)
 Traditional systemic 694 (27.7%) 290 (21.1%) 126 (22.5%) 278 (48.4%)
use in France (odds ratio [OR] 5.38, 95% confidence interval 
[CI] 3.32–8.77), Spain (OR 2.71, 95% CI 1.16–6.33), and 
the UK (OR 8.70, 95% CI 3.65–20.83). Consistent with 
this is our finding that patients with psoriatic arthritis had a 
greater prevalence of PASI score-based moderate-to-severe 
disease as compared with those patients with psoriasis only 
(Figure 1).
Physician-assessed moderate-to-severe disease was also 
a statistically significant predictor of increased biologic 
use in France (OR 5.08, 95% CI 2.01–12.82), Spain (OR 
11.11, 95% CI 4.33–28.57), and the UK (OR 8.55, 95% CI 
1.11–66.67).
No other variables were consistent across countries, 
although higher PASI scores increased the odds of using 
biologics in France (OR 1.05, 95% CI 1.02–1.08) and Spain 
(OR 1.02, 95% CI 1.00–1.05). Obesity was found to be 
associated with increased odds of biologic use only in France 
(OR 2.29, 95% CI 1.33–3.95).
Discussion
In this study, an average of about one tenth of psoriasis 
patients enrolled in Spain, France, and the UK were treated 
with biologics in 2007. The European Medicines Agency 
requires that only those patients with moderate-to-severe 
psoriasis and an inadequate response to conventional sys-
temic medications (or adverse effects/contraindication to 
these agents) are eligible for prescription of biologics in 
the European Union.13–16 The primary caveat to the assess-
ment of patient eligibility for biologic treatment in this 
study is the lack of information in the Adelphi database on 
patient history regarding response to conventional therapies. 
Although a determination of moderate-to-severe disease 
implies prior therapies had been ineffective, the proportion 
of patients who had failed to respond to conventional 
therapies was unknown, and therefore the true percent-
age of eligible patients cannot be determined. However, 
the mean PASI score was found to be significantly higher 
among patients on biologic treatment than in those with 
nonbiologic treatment in France (P,0.0001) and in Spain 
one quarter of patients in France (25.8%) and Spain (29.4%) 
had nail involvement, but the percentage was numerically 
higher in the UK (42.5%). In our bivariate assessment of 
patient characteristics associated with biologic use, psoriatic 
arthritis was significantly associated with biologic use in all 
three countries. Obesity, PASI score, and nail involvement 
were also found to be significantly associated with biologic 
use in patients from France and Spain.
Patient characteristics associated  
with biologic use
Use of biologics was reported in 11.2% (n=282) of the 
total patient population (Table 2). Biologic use was most 
prevalent in Spain (19.4%), followed by France (9.1%) and 
the UK (8.4%). Among patients with physician-assessed 
mild disease, biologic use was 8.2% in France, 12.8% in 
Spain, and 7.1% in the UK (Table 3). Among patients with 
physician-assessed moderate-to-severe psoriasis, biologic use 
was 27.8% in Spain, followed by France (9.7%) and the UK 
(9.3%). Physician-assessed moderate-to-severe disease was 
also significantly associated with biologic use in all three 
countries (all comparisons P,0.0005).
Distribution of psoriasis severity  
and correlation with Pasi score
The distribution of physician-assessed psoriasis severity var-
ied significantly between countries (P,0.001, Table 4). There 
were more patients with mild disease than moderate disease 
and severe disease in Spain (55.6%, 37.6%, and 6.6%, respec-
tively) and the UK (43.9%, 39.4%, and 16.7%,  respectively). 
There were more patients with moderate  disease than mild 
disease and severe disease in France (44.8%, 40.6%, and 
14.6%, respectively). Physician-assessed psoriasis severity 
correlated strongly with PASI scores in each country (Spear-
man coefficient R=0.699, Table 5).
Predictors of biologic use
In the logistic regression analysis (Table 6), psoriatic arthritis 
was a statistically significant predictor of increased biologic 
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Table 4 Physician-assessed current severitya
Physician-assessed  
current severity
France 
(n=1,374)
Spain 
(n=561)
UK 
(n=574)
Mild 558 (40.6%) 312 (55.6%) 252 (43.9%)
Moderate 616 (44.8%) 211 (37.6%) 226 (39.4%)
severe 200 (14.6%) 37 (6.6%) 96 (16.7%)
Note: aPhysician-assessed disease severity by country (P-value ,0.0001).
Table 5 Pasi score by physician-assessed current severitya
Physician-assessed  
current severity
Mean PASI score (n)
France 
(n=1,270)
Spain 
(n=480)
UK 
(n=538)
Mild 5.6 (524) 5.8 (263) 4.6 (240)
Moderate 11.0 (559) 11.4 (181) 11.6 (206)
severe 18.8 (187) 27.9 (36) 23.0 (92)
Note: aR=0.699 for the spearman correlation between physician-assessed severity 
and Pasi score.
Abbreviation: Pasi, Psoriasis area and severity index.
(P,0.0005). There was no significant difference in PASI 
score between patients with biologic treatment and those 
with nonbiologic treatment in the UK. In support of our 
assumption that this determination was accurate is the 
median PASI score, which was 8.2 (mean 9.5), indicating 
that nearly 50% of patients had moderate-to-severe pso-
riasis on the basis of PASI score. In comparison, 39.0% 
of patients with psoriasis had moderate-to-severe disease 
based on a PASI score $10 in a study of patients attending 
dermatology clinics in Germany.21 Similarly, a multinational 
survey in Eastern Europe found that 37% of patients had 
severe disease, defined as a PASI score $10 and a DLQI .10 
(the same as the British Association of  Dermatologists’ 
criteria for moderate-to-severe psoriasis), and were thus 
considered eligible for treatment with  biologics.22 Deter-
minations of the prevalence of moderate-to-severe psoriasis 
based on the percentage of body surface area affected are 
available from the US23 and Canada,24 but they vary widely 
(17%–95% of patients) and may not correlate well with 
PASI-based determinations. However, a survey of Califor-
nia dermatologists in which physician-assessed severity 
was reported showed that 41% of psoriasis patients had 
moderate-to-severe disease.25
Large differences between the adjusted OR and unad-
justed OR can happen with confounding factors introduced. 
In this study, greater psoriasis severity, as indicated by PASI 
score, was not independently associated with biologic treat-
ment. This suggests that European and UK guidelines may not 
strongly influence treatment decisions. However, physician-
assessed severity was found to be a significant predictor of 
biologic use in all three countries. It is interesting to note that 
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Figure 1 Distribution of psoriasis severity* in patients with (A) psoriatic arthritis 
and (B) psoriasis only.
Notes: *severity was determined by Pasi scores as described in the Materials 
and methods section. Distribution of mild versus moderate-to-severe disease was 
significantly different in patients with psoriatic arthritis than those with psoriasis only 
(P#0.004 for each country in chi-square tests). n=1,269 for France, 551 for spain, 
and 507 for the UK.
Abbreviation: Pasi, Psoriasis area and severity index.
Table 6 Predictors of current biologic treatment
Adjusted odds ratio (95% CI)a
France (n=1,266) Spain (n=466) UK (n=333)
increasing age 1.00 (0.99–1.02) 0.99 (0.97–1.00) 0.99 (0.96–1.01)
Female 0.94 (0.62–1.54) 0.79 (0.47–1.32) 1.19 (0.55–2.57)
BMi $30 versus BMi ,30 2.29 (1.33–3.95) 1.38 (0.62–3.13) 1.81 (0.80–4.11)
nail involvement 1.49 (0.96–2.32) 1.30 (0.76–2.25) 0.90 (0.40–2.00)
increasing Pasi score 1.05 (1.02–1.08) 1.02 (1.00–1.05) 1.00 (0.95–1.05)
Moderate-to-severe diseaseb 5.08 (2.01–12.82) 11.11 (4.33–28.57) 8.55 (1.11–66.67)
Psoriatic arthritis 5.38 (3.32–8.77) 2.71 (1.16–6.33) 8.70 (3.65–20.83)
Notes: aBold text indicates statistical significance; bphysician-assessed disease severity, moderate and severe patients are combined.
Abbreviations: BMI, body mass index; CI, confidence interval; PASI, Psoriasis Area and Severity Index.
a subjective assessment of physician severity, which was done 
by dermatologists presumably familiar with the diagnosis 
and management of psoriasis, was found to be a significant 
predictor, and not PASI score, which is an objective measure. 
A physician’s severity assessment may be driving the treat-
ment decision to prescribe biologics rather than an objective 
measure in clinical practice. However, the lack of association 
might speak to the imputation method used to calculate PASI 
score for those patients where it was missing.
The PASI index does not specifically include nail psoria-
sis or the presence of psoriatic arthritis, which may reflect 
greater disease severity. Although these other variables 
related to disease severity were negatively associated with 
biologic treatment in the bivariate analyses, psoriatic arthritis 
was predictive of treatment with biologics in the regres-
sion model (statistically significant for Spain, numerically 
so for France), consistent with the greater disease severity 
observed in patients with psoriatic arthritis. According to 
Spanish guidelines, the presence of arthritis is a criterion for 
prescription of biologics.26 Because of the cross-sectional 
design of this study, we could not tell whether biologic use 
was the reason for lower PASI scores. We must speculate that 
the effectiveness of biologic therapy was at least part of the 
reason for the negative association.
To date there are no reliable predictors of response 
to tumor necrosis factor-alpha antagonists as a class 
(regardless of disease),27 and few studies have been per-
formed to identify genetic predictors of response to biologics 
in psoriasis.28 Studies of variables associated with the clinical 
response of psoriatic arthritis to tumor necrosis factor-alpha 
antagonists have identified younger age29,30 and male sex.29,31 
In the present study, both age and female sex were not predic-
tive of treatment with biologics.
Several limitations in this analysis stem from the data 
source. The data set refers to treatment patterns in 2007, 
which do not necessarily reflect current trends in biologic 
use. The proportions of patients seen in this study are 
not representative of psoriasis patients in general. The 
majority of mild-moderate patients are seen primarily by 
primary care practices. Further, as noted above, there was 
no documentation of prior failure to respond to conventional 
therapies. Data on PASI scores were not available for all 
patients. The paucity of PASI scores in the database required 
imputation of scores for most of the study  population. As 
stated in the Materials and methods section, the correlation 
between actual and predicted PASI scores was moderate 
(R=0.51). In addition, we observed no difference between 
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actual and imputed mean PASI scores for patients treated 
with biologics versus patients treated with nonbiologics 
(including topicals only, phototherapy, and conventional 
systemic therapy).
In conclusion, an average of about one tenth of the 
psoriasis patients enrolled in this study in Spain, France, 
and the UK were treated with biologics. Physician-assessed 
moderate-to-severe disease and the presence of psoriatic 
arthritis were significantly predictive of biologic use in all 
three countries.
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